ENTA
Price
$10.96
Change
-$0.53 (-4.61%)
Updated
Oct 14, 04:59 PM (EDT)
Capitalization
331.52M
34 days until earnings call
Intraday Buy/Sell Signals
MRUS
Price
$94.85
Change
-$0.00 (-0.00%)
Updated
Oct 14, 04:59 PM (EDT)
Capitalization
7.19B
16 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ENTA vs MRUS

Header iconENTA vs MRUS Comparison
Open Charts ENTA vs MRUSBanner chart's image
Enanta Pharmaceuticals
Price$10.96
Change-$0.53 (-4.61%)
Volume$10.89K
Capitalization331.52M
Merus
Price$94.85
Change-$0.00 (-0.00%)
Volume$6.42K
Capitalization7.19B
ENTA vs MRUS Comparison Chart in %
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. MRUS commentary
Oct 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and MRUS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 14, 2025
Stock price -- (ENTA: $11.49 vs. MRUS: $94.85)
Brand notoriety: ENTA and MRUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 70% vs. MRUS: 98%
Market capitalization -- ENTA: $331.52M vs. MRUS: $7.19B
ENTA [@Biotechnology] is valued at $331.52M. MRUS’s [@Biotechnology] market capitalization is $7.19B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileMRUS’s FA Score has 1 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • MRUS’s FA Score: 1 green, 4 red.
According to our system of comparison, MRUS is a better buy in the long-term than ENTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 6 TA indicator(s) are bullish while MRUS’s TA Score has 4 bullish TA indicator(s).

  • ENTA’s TA Score: 6 bullish, 4 bearish.
  • MRUS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than MRUS.

Price Growth

ENTA (@Biotechnology) experienced а +1.23% price change this week, while MRUS (@Biotechnology) price change was +0.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.52%. For the same industry, the average monthly price growth was +13.94%, and the average quarterly price growth was +279.73%.

Reported Earning Dates

ENTA is expected to report earnings on Nov 17, 2025.

MRUS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+0.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRUS($7.19B) has a higher market cap than ENTA($332M). MRUS YTD gains are higher at: 125.565 vs. ENTA (99.826). ENTA has higher annual earnings (EBITDA): -82.41M vs. MRUS (-347.56M). MRUS has more cash in the bank: 710M vs. ENTA (204M). MRUS has less debt than ENTA: MRUS (11M) vs ENTA (58M). ENTA has higher revenues than MRUS: ENTA (64.8M) vs MRUS (56.2M).
ENTAMRUSENTA / MRUS
Capitalization332M7.19B5%
EBITDA-82.41M-347.56M24%
Gain YTD99.826125.56580%
P/E RatioN/AN/A-
Revenue64.8M56.2M115%
Total Cash204M710M29%
Total Debt58M11M527%
FUNDAMENTALS RATINGS
ENTA vs MRUS: Fundamental Ratings
ENTA
MRUS
OUTLOOK RATING
1..100
8432
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
1008
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3736
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRUS's Valuation (54) in the Biotechnology industry is somewhat better than the same rating for ENTA (99). This means that MRUS’s stock grew somewhat faster than ENTA’s over the last 12 months.

MRUS's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for ENTA (100). This means that MRUS’s stock grew significantly faster than ENTA’s over the last 12 months.

MRUS's SMR Rating (98) in the Biotechnology industry is in the same range as ENTA (98). This means that MRUS’s stock grew similarly to ENTA’s over the last 12 months.

MRUS's Price Growth Rating (36) in the Biotechnology industry is in the same range as ENTA (37). This means that MRUS’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for MRUS (100). This means that ENTA’s stock grew significantly faster than MRUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTAMRUS
RSI
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 7 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
72%
Bearish Trend 7 days ago
82%
Momentum
ODDS (%)
Bullish Trend 7 days ago
70%
Bullish Trend 7 days ago
90%
MACD
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 7 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
83%
Advances
ODDS (%)
Bullish Trend 16 days ago
71%
Bullish Trend 15 days ago
83%
Declines
ODDS (%)
Bearish Trend 13 days ago
83%
Bearish Trend 29 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 7 days ago
83%
Aroon
ODDS (%)
Bullish Trend 7 days ago
70%
Bullish Trend 7 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GRWXF5.500.36
+7.00%
MOLTEN VENTURES PLC
PABD63.180.68
+1.09%
iSharesParis-AlgndClmOptdMSCIWldexUSAETF
EFAA52.620.37
+0.71%
Invesco MSCI EAFE Income Advantage ETF
BMEZ14.810.03
+0.20%
BlackRock Health Sciences Term Trust
HRTS32.16-0.02
-0.07%
Tema Heart & Health ETF

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with MRUS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then MRUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+4.26%
MRUS - ENTA
50%
Loosely correlated
+0.51%
ORKA - ENTA
37%
Loosely correlated
+4.14%
ANAB - ENTA
35%
Loosely correlated
+3.47%
AKRO - ENTA
34%
Loosely correlated
-0.41%
VRDN - ENTA
34%
Loosely correlated
+1.81%
More

MRUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with NUVL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
+0.51%
NUVL - MRUS
51%
Loosely correlated
+1.87%
ENTA - MRUS
50%
Loosely correlated
+4.26%
CGON - MRUS
48%
Loosely correlated
-0.67%
RVMD - MRUS
47%
Loosely correlated
+1.06%
IDYA - MRUS
43%
Loosely correlated
+2.02%
More